Meddenovo builds an AI-powered molecular modelling platform specifically designed to harness the properties of cyclic peptides for drug discovery. The company positions its platform as uniquely focused on cyclic peptides to address therapeutically relevant targets. It is targeting diseases including cancer, autoimmune disorders, and antimicrobial resistance. Founders Dr Ilke Ugur Marion (co-founder and CEO) and Dr Antoine Marion (co-founder and CTO) bring drug-development, scientific research, project management, and computational chemistry expertise. Meddenovo raised up to €1 million in a Pre-seed round to accelerate R&D, enhance its AI-driven platforms, and expand its customer base and partnerships. The company plans to transition from a service-based model to a Software-as-a-Service (SaaS) offering and to pursue co-development opportunities with pharmaceutical and biotech partners.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2024